(Reuters) - New Zealand medical device firm Fisher & Paykel Healthcare <FPH.NZ> on Thursday raised its full-year profit guidance by more than two percent as it benefited from a weakening in the New Zealand dollar.
The firm, which generates a majority of its revenue outside New Zealand, now expected annual net profit of about NZ$215 million ($142.67 million), higher than its previous guidance of about NZ$210 million.
"This year, the New Zealand dollar has weakened against a number of other currencies, which is the major contributor to the upgrade in our earnings guidance," Managing Director and CEO Lewis Gradon said.
The New Zealand dollar <NZD=D3> has fallen more than 5 percent so far in 2018.
The company also upgraded its operating revenue guidance to about NZ$1.07 billion, compared to a previous forecast of about NZ$1.05 billion.
(Reporting by Aditya Soni in Bengaluru; Editing by Darren Schuettler)
